Bioventix (FRA:51B) Moat Score: 0/10 (As of Jul. 09, 2026)


FRA:51B Bioventix PLC FRA:51B
64 GF Score
Price €17.50
GF Value €38.68
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioventix Moat Score?

Bioventix has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Bioventix has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioventix might have No Moat - No discernible moat.

Bioventix  (FRA:51B) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioventix Moat Score Related Terms

FRA:51B
64GF Score
Bioventix PLC FRA:51B
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioventix (FRA:51B) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventix stock appears to be undervalued. The current stock price of €17.50 is trading 54.8% below its estimated GF Value™ of €38.68. GuruFocus considers Bioventix to be Significantly Undervalued.

Key valuation signals for FRA:51B:

  • Moat Score: 0
  • GF Value™: €38.68 vs. price of €17.50 (54.8% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the FRA:51B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventix Business Description

Other Exchanges BVXP:UK
Address 27-28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
64GF Score

Get the complete analysis for FRA:51B

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.50
Price
€38.68
GF Value